Why the study?
Cisplatin-based chemotherapy for metastatic testicular cancer is associated with long-term cardiovascular risk and cisplatin persists for decades, but its cardiac impact 30 years post-treatment required evaluation.
Does cisplatin-based chemotherapy worsen long-term cardiac function and morphology in testicular cancer survivors?
Does cisplatin-based chemotherapy worsen long-term cardiac function and morphology in testicular cancer survivors?
Three decades after cisplatin-based chemotherapy, testicular cancer survivors show worse diastolic function and higher rates of metabolic dysfunction, but no overt reduction in systolic function.
No takes yet. Share an insight, caveat, or question.
Diastolic monitoring may be warranted in long-term TC survivors; leaves open whether cisplatin drives these changes.
Bjerring et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: